Instem Taps ex-Novartis Head of Emerging Technologies to Put Science Behind Practical AI and NAMsBusiness Wire • 04/15/26
Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030GlobeNewsWire • 04/09/26
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%GlobeNewsWire • 03/29/26
Novartis to acquire Excellergy, strengthening allergy pipeline with next-generation anti-IgE therapyProactive Investors • 03/27/26
Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a weekCNBC • 03/27/26
Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitorsGlobeNewsWire • 03/27/26
Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovationGlobeNewsWire • 03/27/26
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026GlobeNewsWire • 03/23/26
Novartis to Acquire Synnovation Therapeutics' Pan-Mutant Selective PI3Kα Inhibitor ProgramBusiness Wire • 03/20/26
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipelineGlobeNewsWire • 03/20/26
Big drugmakers must face US overcharge claims on medications for low-income patientsReuters • 03/17/26
FDA Approves NVS' Cosentyx in Hidradenitis Suppurativa for AdolescentsZacks Investment Research • 03/16/26